Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02460679 · ClinicalTrials.gov registry record · Phase 2
Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study, sponsored by PTC Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT02460679 is a Phase 2 study that has completed, run by PTC Therapeutics. The registered enrollment target is 19 participants.
The verdict
NCT02460679, a Phase 2 study, has completed, sponsored by PTC Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is an open label study with 30-day run in phase to establish baseline parameters, 90-day treatment phase, and a 90-day withdrawal phase to determine long-term effects, duration of treatment response, and potential effects of EPI-589 therapy on known trajectory.
Interventions
- DRUG EPI-589
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-01-14 |
| Est. Completion | 2018-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02460679
The ClinicalTrials.gov registry entry for NCT02460679 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PTC Therapeutics, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EPI-589 is the first listed.
NCT02460679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02460679 about?
NCT02460679 is a clinical study titled "Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)". This is an open label study with 30-day run in phase to establish baseline parameters, 90-day treatment phase, and a 90-day withdrawal phase to determine long-term effects, duration of treatment response, and potential effects of EPI-589 therapy on known trajectory.
What is the current status of trial NCT02460679?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2016-01-14. Estimated completion is 2018-02-23.
What interventions are being tested in trial NCT02460679?
The interventions under investigation include: EPI-589 (DRUG).
Who is sponsoring clinical trial NCT02460679?
This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.